I-Mab Biopharma, a clinical-stage biopharmaceutical company, has received a strategic investment from Everest Medicines and priced a $65 million offering of American Depositary Shares to support its clinical development programs.

I-Mab Biopharma, a clinical-stage biopharmaceutical company, has made significant strides in cancer treatment with promising results from its gastric cancer medication and Phase 1b study, solidifying its position as a beacon of hope in the fight aga…